AdvisorShares Pure US Cannabis ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-6.15%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-14.61%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-36.44%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y-51.88%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-66.95%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range13.16 - 42.06 Perf YTD-46.35%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-67.36% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low4.33% ATR0.76
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)36.03 Volatility4.25% 5.74%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.66 Prev Close13.90
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume1.38M Price13.73
Recom- SMA20-3.33% SMA50-20.22% SMA200-43.74% Volume2,292,806 Change-1.22%
May-26-22 04:19PM  
May-25-22 02:00PM  
May-19-22 11:04AM  
May-11-22 08:20AM  
May-09-22 08:04AM  
May-05-22 08:42AM  
Apr-29-22 08:13AM  
Apr-28-22 06:45PM  
Apr-19-22 02:02PM  
Apr-14-22 07:24PM  
Apr-12-22 09:17AM  
Apr-01-22 01:15PM  
Mar-31-22 04:00AM  
Mar-10-22 08:58AM  
Mar-04-22 11:16AM  
Feb-23-22 12:05PM  
Feb-22-22 11:03AM  
Feb-15-22 08:23AM  
Feb-10-22 04:20PM  
Nov-17-21 05:20PM  
Nov-16-21 10:03AM  
Nov-15-21 10:45AM  
Sep-16-21 11:00AM  
Jul-02-21 11:30AM  
May-14-21 11:00AM  
May-11-21 12:23PM  
Apr-21-21 08:37AM  
Apr-20-21 03:03PM  
Apr-19-21 01:58PM  
Mar-01-21 05:00PM  
Feb-23-21 09:00AM  
Feb-09-21 12:41PM  
Jan-28-21 04:10PM  
Jan-12-21 07:00AM  
Jan-11-21 08:03AM  
Jan-07-21 08:03AM  
Jan-06-21 04:29PM  
Dec-23-20 11:07AM  
Nov-23-20 05:30PM  
Nov-18-20 01:18PM  
Nov-05-20 12:00PM  
Nov-04-20 05:10PM  
Nov-01-20 07:59AM  
Oct-13-20 04:15PM  
Sep-09-20 10:06AM  
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from the marijuana and hemp business in the United States and in derivatives that have economic characteristics similar to such securities. It will concentrate at least 25% of its investments in the pharmaceuticals, biotechnology & life sciences industry group within the health care sector. The fund is non-diversified.